Fig. 4.

Phosphorylated signaling after drug treatment. (A) pY immunoblot of H929 lysate after 24-h incubation with various tyrosine kinase inhibitor drugs including imatinib and the proteasome inhibitor bortezomib. (B) Immunoblots showing the effect of 1-h treatment of increasing concentrations of imatinib on key signaling proteins pERK, pAKT, and pS6K from WCL of BCR–ABL fusion containing cells H929 (MM) and K562 (CML) as well as RPMI-8226 MM cells containing no BCR–ABL fusion and 293T cells for a control.